



LifeSciences



## Genesis

- A 32-years old research-driven company headquartered in Hyderabad.
- SMS Lifesciences India Limited has been demerged from SMS Pharmaceuticals Limited in 2017
- API focused company with 4 world-class facilities including its subsidiary Mahi Drugs in Vizag & associate firm R-Chem(Somanahalli) in Humnabad, Karnataka.

## Integrated model

- More than 80% of the intermediates are consumed by in-house business. Low import dependency.
- Backward integrated up to the KSM stage for majority of the API's supported by associate firms Mahi Drugs Pvt. Ltd. and R Chem (Somanahalli) Pvt. Ltd.
- Gained significant resilience to supply chain disruptions, market power, and achieved economies of scale

## API Business

- ~80% of revenue is derived through API business
- Achieved global and domestic leadership in majority of the key complex, specialized products like Ranitidine, Famotidine, Sildenafil, Ropivacaine HCl
- Formed exclusive development and CDMO partnership with ChemWerth, USA through Mahi Drugs to accelerate new product selection & development.

## CRAMS Business

- Engaged in providing quality alternative manufacturing destination to multinationals for their contract research and manufacturing needs.
- Top Customers: Mylan, Chemo, Dr. Reddy's , Laurus & Lupin
- Multiple manufacturing facilities to support various range and capacity of Intermediates and APIs starting from as small as 0.065 KL up to as large as 15KL

## Reach


- 500+ Customers
- 70+ Countries
- 25+ Products
- 40+ Regulatory Fillings
- 25+ Process Patents



## Capacity Overview


- Installed Capacity: 980 KL across group firms; 150KL planned in next 1 year
- Inhouse R&D Facility with 50+ scientists working with focus on novel route synthesis, analytical method development, process robustness and cost effectiveness.
- Certifications: USFDA, KFDA, PMDA, COFEPRIS, WHO-GMP, CDCSO, DSIR and ISO


# Transformation Over the Years





# State-of-the-art Manufacturing Facilities

 Corporate Headquarters in Hyderabad



Unit-1



R&D




Unit-4



Particulars	SMS Lifesciences	
Unit	Unit-1	Unit-4
City, State	Hyderabad, Telangana	Hyderabad, Telangana
Year of Establishment	1989	1996
Installed Capacity	570KL	50KL
Key Products	Ranitidine, Famotidine, Sildenafil, Ropivacaine, Allopurinol, Dapsone, Furosemide, Domperidone etc.	Sibutramine, Famotidine, Itraconazole
Regulatory Approvals	USFDA, PMDA, KFDA, COFEPRIS, CDSCO	CDSCO, GMP
Key Features	<ul style="list-style-type: none"> <li>2 times USFDA Approved</li> <li>Facility aligned to manufacture medium to large scale APIs</li> <li>Largest Exporter of Ranitidine, Famotidine and Ropivacaine</li> <li>Large CMO intermediate facility built to cater to highly reputed clients</li> </ul>	<ul style="list-style-type: none"> <li>Facility aligned for manufacturing niche small volume molecules.</li> <li>Largest exporter of Sibutramine.</li> </ul>

# State-of-the-art Manufacturing Facilities

 Corporate Headquarters in Hyderabad




**R|CHEM**  
(Somanahalli) Pvt. Ltd.,



Particulars	Mahi Drugs Pvt. Ltd	RChem (Somanahalli) Pvt. Ltd
<b>Relationship with SMS</b>	Subsidiary of SMS Lifesciences	Associate Firm with 100% equity holding by SMS Lifesciences promoters
<b>City, State</b>	Vizag, Andhra Pradesh	Bidar, Karnataka
<b>Year of Establishment/ Acquisition</b>	2018	2005
<b>Installed Capacity</b>	230 KL	130KL (150 KL Capacity addition in 2023)
<b>Key Products</b>	Fosphenytoin Sodium, Albendazole, Mirtazapine, Trazadone, Famotidine, Hydroxine Hcl etc.	Advance Intermediates and KSM for Ranitidine, Cimetidine, Rilpivirine, Mirtazapine, Famotidine etc. APIs
<b>Regulatory Approvals</b>	CDSCO, ISO (USFDA –Expected 2023)	USFDA, PMDA, ISO
<b>Key Features</b>	<ul style="list-style-type: none"> <li>Facility aligned to manufacture small to large scale APIs</li> <li>World class pilot plant and API/Intermediate facility for customer's diverse requirements.</li> </ul>	<ul style="list-style-type: none"> <li>Facility aligned for manufacturing KSMs/Intermediates for inhouse and customer requirements.</li> <li>Contract manufacturing of intermediates for regulated markets.</li> </ul>

# Strong Thrust on R&D and Regulatory






# Self-Reliant Manufacturing Plants



- Pre-treatment plant capacity (MGF, Softner) – 5000 lts/hr
  - DM Water Generation by RO & EDI - 3000lts/hr
  - DM Water Storage Capacity - 6000 Lts
- Vacuum System (0.1 Torr) & Nitrogen Plant 200 NM<sup>3</sup>/ Hr.
- 3 X 8 Tons ; 1 x 4 Ton ; 2 x 3 Tons ; 1 x 1 Ton boiler
- ZLD Treatment Facilities with capacity of up to 150 KLD across firms
- Warehouses self equipped to store all types and temperature raw materials.

## Wide Array of Manufacturing Capabilities across group firms

Particulars	No.
Production Blocks	11
Pharma Lines	6
Total Number of Reactors	228
Minimum Size	65L
Maximum Size	15 KL
Total Capacity	980 KL
Glass Lined Reactors	80
SS Reactors	148
Hydrogenators	5
Distillation Columns	10
Glass Flasks	1
Centrifuges	32
Dryers	47



- Can maintain minimum temperature of -70°C and maximum temperature of 220°C, at pressures up to 25kgs in the reactor while manufacturing various products in our plant.
- Capable to perform High vacuum distillation at vacuum levels of 0.1 Torr.
- Experience in handling the diverse chemical reactions for various APIs and Intermediates of different therapeutic categories to human consumption manufactured on site



# All while Maintaining GMP and Highest Level of Compliance



- ☐ Successfully completed 12 USFDA audits since first audit in 2003. Majority of the USFDA audits were closed with ZERO 483.
- ☐ Last audit completed in Apr'22 with zero 483.

# ...Resulting in Long Lasting Relationships with Marquee Clients

Dr.Reddy's



SUN  
PHARMA

Cipla

CHEMWERTH

Zydus  
dedicated to life



Mylan®



torrent  
PHARMA

teva



LAURUS Labs  
Knowledge . Innovation . Excellence



c<sup>2</sup> PHARMA



AUROBINDO



CHEMO  
Global Affinity in Healthcare



gsk



glenmark  
A new way for a new world




ALKEM

## Areas of Focus



Financial Year	Scheduled Head	Particulars
FY 2022-23	Rural Development	Construction of multifarious skill development centre in Kazipally area.
	Health care	Infrastructure and logistic support to the Public Healthcare Centre building in Kazipally village.
FY 2021-22:	Disaster Management	Setting up of conversation of PSA Nitrogen plant to PSA Oxygen Plant in Gandhi hospital, Hyderabad, to cater Covid crisis.
	Sanitation	Construction of Public Healthcare Centre (PHC) building in Kazipally village
FY 2020-21:	Promoting education	Construction of school building in TNSZP High School, Elamanchili village, East Godavari, AP
	Disaster Management	Distribution of food during Covid19 pandemic in Kazipally and Jeedimetla area of Hyderabad
		Spreading awareness of Covid19 pandemic
	Rural Development	Construction of public road in Kazipally industrial area for the common beneficiary.
	Environmental sustainability	Supply of Tree guards at Kazipally area
	Sanitation	Garbage collecting e-vehicle in Elamanchili village and Utada village, East Godavari Dist., AP
		Construction of toilets in Veterinary Hospital, Elamanchili village, East Godavari, AP
FY 2019-20:	Promoting Education	Construction of Anganwadi School building, Kazipally. Renovation of TNSZP High School, Elamanchili village
	Promoting Sanitation	Construction of public toilets at Elamanchili village Repair of e-cart waste collecting vehicle
	Health-care	Distribution of Dustbins.
FY 2018-19:	Promoting education	Construction of Anganwadi School building, Kazipally. Support to Udbhav School for the education of girl child
	Upliftment of weaker section	Contribution for the welfare of the weaker section







*Thank  
you*

